Jane Street’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Jane Street’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,910	Closed	-$219K	–	10948
2021 Q3	$219K	Sell	4,910 -340	-6%	-$16.6K	﹤0.01%	8718
2021 Q2	$286K	Buy	5,250 +500	+11%	+$29.6K	﹤0.01%	8229
2021 Q1	$355K	Buy	+4,750	New	+$493K	﹤0.01%	7425

Other funds holding SYRS

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

1CM

1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Jane Street's SYRS Position: Q1 2025 in Review

Jane Street sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 52,920 shares — an estimated $12.2K sold.

Jane Street first reported a position in SYRS in Q4 2020 and held it in 12 quarters. The position peaked at $923K in Q1 2024. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

Jane Street reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Jane Street sold 52,920 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $12.2K.
Jane Street first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 12 quarters.
Jane Street's Syros Pharmaceuticals, Inc. Common Stock position peaked at $923K in Q1 2024.
7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Jane Street's 13F filing for Q1 2025, filed 14 May 2025.